Unlike mature targeted therapies for oncogene-driven NSCLC such as epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), there is currently no approved standard targeted therapy for NSCLC with HER2 alterations (2). The gene discussed is ALK; the disease is non-small cell lung carcinoma.